AIMS/HYPOTHESIS: In type 2 diabetic patients, insulin detemir (B29Lys(ε-tetradecanoyl),desB30 human insulin) induces less weight gain than NPH insulin. Due to the proposed reduction of tubular action by insulin detemir, type 2 diabetic patients should have increased urinary sodium excretion, thereby reducing extracellular volume and body weight when changed from NPH insulin to insulin detemir. METHODS: In a randomised, open-labelled, two-way crossover study of 24 patients with type 2 diabetes, patients were first treated withNPH insulin or insulin detemir for 8 weeks. Thereafter, they were changed to the other insulin for 8 weeks. In a third 1 week period, they were changed back to the first insulin. RESULTS: At the end of 8 weeks, body weight was reduced by 0.8 ± 0.2 kg (mean ± SEM) on insulin detemir compared with NPH insulin (p < 0.01). After insulin detemir treatment, we also observed a significant reduction of lean body mass (0.8 ± 0.2 kg, p < 0.05) and a non-significant reduction of extracellular volume (0.8 ± 0.5 l/1.73 m², p = 0.14). The weight loss occurred after as early as 1 week (0.8 ± 0.2 kg, p < 0.001), with a simultaneous and transient increase of urinary sodium excretion (p = 0.07). CONCLUSIONS/ INTERPRETATION:Insulin detemir induces significant and sustained weight loss, which is first observed at 1 week after changing from NPH insulin. The initial weight loss seems to be related to changes in fluid volume and may reflect changed insulin action in the kidneys.
RCT Entities:
AIMS/HYPOTHESIS: In type 2 diabeticpatients, insulindetemir (B29Lys(ε-tetradecanoyl),desB30 humaninsulin) induces less weight gain than NPH insulin. Due to the proposed reduction of tubular action by insulindetemir, type 2 diabeticpatients should have increased urinary sodium excretion, thereby reducing extracellular volume and body weight when changed from NPH insulin to insulin detemir. METHODS: In a randomised, open-labelled, two-way crossover study of 24 patients with type 2 diabetes, patients were first treated with NPH insulin or insulindetemir for 8 weeks. Thereafter, they were changed to the other insulin for 8 weeks. In a third 1 week period, they were changed back to the first insulin. RESULTS: At the end of 8 weeks, body weight was reduced by 0.8 ± 0.2 kg (mean ± SEM) on insulindetemir compared with NPH insulin (p < 0.01). After insulindetemir treatment, we also observed a significant reduction of lean body mass (0.8 ± 0.2 kg, p < 0.05) and a non-significant reduction of extracellular volume (0.8 ± 0.5 l/1.73 m², p = 0.14). The weight loss occurred after as early as 1 week (0.8 ± 0.2 kg, p < 0.001), with a simultaneous and transient increase of urinary sodium excretion (p = 0.07). CONCLUSIONS/ INTERPRETATION:Insulindetemir induces significant and sustained weight loss, which is first observed at 1 week after changing from NPH insulin. The initial weight loss seems to be related to changes in fluid volume and may reflect changed insulin action in the kidneys.
Authors: S V M Hordern; J E Wright; A M Umpleby; F Shojaee-Moradie; J Amiss; D L Russell-Jones Journal: Diabetologia Date: 2005-02-24 Impact factor: 10.122
Authors: P Skøtt; O Hother-Nielsen; N E Bruun; J Giese; M D Nielsen; H Beck-Nielsen; H H Parving Journal: Diabetologia Date: 1989-09 Impact factor: 10.122
Authors: A Zanchi; M Maillard; F R Jornayvaz; M Vinciguerra; P Deleaval; J Nussberger; M Burnier; A Pechere-Bertschi Journal: Diabetologia Date: 2010-04-23 Impact factor: 10.122
Authors: B Feldt-Rasmussen; E R Mathiesen; T Deckert; J Giese; N J Christensen; L Bent-Hansen; M D Nielsen Journal: Diabetologia Date: 1987-08 Impact factor: 10.122
Authors: K Nørgaard; T Jensen; P Skøtt; B Thorsteinsson; N E Bruun; J Giese; B Feldt-Rasmussen Journal: Scand J Clin Lab Invest Date: 1991-06 Impact factor: 1.713
Authors: Hye Jin Yoo; Keun Yong Park; Kang Seo Park; Kyu Jeung Ahn; Kyung Wan Min; Jeong Hyun Park; Sang Ah Chang; Bong Soo Cha; Dong-Jun Kim; Yong Seong Kim; Tae Keun Oh; Suk Chon; Il Seong Nam-Goong; Mi Jin Kim; Hye-Soon Kim; Young Sik Choi; You Hern Ahn; Sora Lee; Sei Hyun Baik Journal: Diabetes Metab J Date: 2013-06-14 Impact factor: 5.376
Authors: D Russell-Jones; T Danne; K Hermansen; K Niswender; K Robertson; N Thalange; J R Vasselli; B Yildiz; H U Häring Journal: Diabetes Obes Metab Date: 2015-08-11 Impact factor: 6.577